{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:01:19Z","timestamp":1790470879236,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.heliyon.2023.e16665","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T21:22:49Z","timestamp":1684963369000},"page":"e16665","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Reduced C-reactive protein level at hospital admission in patients treated with Tocilizumab \u2013 An attention may be required"],"prefix":"10.1016","volume":"9","author":[{"given":"Mark","family":"Berman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomo","family":"Berliner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Bashouti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ori","family":"Elkayam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2589-8473","authenticated-orcid":false,"given":"Tomer","family":"Ziv-Baran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2023.e16665_bib1","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3389\/fimmu.2018.00754","article-title":"Role of C-reactive protein at sites of inflammation and infection","volume":"9","author":"Sproston","year":"2018","journal-title":"Front. Immunol."},{"issue":"16","key":"10.1016\/j.heliyon.2023.e16665_bib2","doi-asserted-by":"crossref","first-page":"9503","DOI":"10.1074\/jbc.271.16.9503","article-title":"STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6","volume":"271","author":"Zhang","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e16665_bib3","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3109\/07853890009011772","article-title":"Function of C-reactive protein","volume":"32","author":"Du Clos","year":"2000","journal-title":"Ann. Med."},{"issue":"7545","key":"10.1016\/j.heliyon.2023.e16665_bib4","first-page":"838","volume":"332","author":"Healy","year":"2006","journal-title":"Infections. BMJ"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e16665_bib5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/rheumatology\/keg263","article-title":"Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy","volume":"42","author":"Kroesen","year":"2003","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.heliyon.2023.e16665_bib6","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0749-0704(02)00022-2","article-title":"Infections in the immunocompromised rheumatologic patient","volume":"18","author":"Greenberg","year":"2002","journal-title":"Crit. Care Clin."},{"key":"10.1016\/j.heliyon.2023.e16665_bib7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jcrc.2017.07.025","article-title":"Accuracy of C - Reactive protein as a bacterial infection marker in critically immunosuppressed patients: a systematic review and meta-analysis","volume":"42","author":"de Oliveira","year":"2017","journal-title":"J. Crit. Care"},{"issue":"3","key":"10.1016\/j.heliyon.2023.e16665_bib8","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3390\/life11030258","article-title":"The effect of tocilizumab on inflammatory markers in patients hospitalized with serious infections. Case series and review of literature","volume":"11","author":"Berman","year":"2021","journal-title":"Life"},{"issue":"16","key":"10.1016\/j.heliyon.2023.e16665_bib9","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with covid-19","volume":"384","author":"Gordon","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10285","key":"10.1016\/j.heliyon.2023.e16665_bib10","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","year":"2021","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.heliyon.2023.e16665_bib11","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","article-title":"Infections in patients with rheumatoid arthritis treated with biologic agents","volume":"52","author":"Listing","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e16665_bib12","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chron. Dis."},{"key":"10.1016\/j.heliyon.2023.e16665_bib13","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.cca.2019.04.073","article-title":"Characteristics of apparently healthy individuals with a very low C-reactive protein","volume":"495","author":"Ziv-Baran","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.heliyon.2023.e16665_bib14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cca.2017.06.008","article-title":"The ability of the wide range CRP assay to classify individuals with low grade inflammation into cardiovascular risk groups","volume":"471","author":"Ziv-Baran","year":"2017","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.heliyon.2023.e16665_bib15","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2119\/molmed.2016.00067","article-title":"Weakened cholinergic blockade of inflammation associates with diabetes-related depression","volume":"22","author":"Shenhar-Tsarfaty","year":"2016","journal-title":"Mol. Med."},{"issue":"11","key":"10.1016\/j.heliyon.2023.e16665_bib16","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/ncprheum0338","article-title":"Interleukin 6: from bench to bedside","volume":"2","author":"Nishimoto","year":"2006","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"10.1016\/j.heliyon.2023.e16665_bib17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cca.2018.03.022","article-title":"C-reactive protein and emergency department seven days revisit","volume":"481","author":"Ziv-Baran","year":"2018","journal-title":"Clin. Chim. Acta"},{"issue":"10","key":"10.1016\/j.heliyon.2023.e16665_bib18","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/acr.23303","article-title":"Treatment of rheumatoid arthritis with anti-tumor necrosis factor or tocilizumab therapy as first biologic agent in a global comparative observational study","volume":"69","author":"Choy","year":"2017","journal-title":"Arthritis Care Res."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e16665_bib19","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.heliyon.2023.e16665_bib20","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e16665_bib21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","article-title":"Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations","volume":"21","author":"McInnes","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.heliyon.2023.e16665_bib22","first-page":"160","article-title":"The role of interleukin 6 in megakaryocyte formation, megakaryocyte development and platelet production","volume":"167","author":"Williams","year":"1992","journal-title":"Ciba Found. Symp."},{"key":"10.1016\/j.heliyon.2023.e16665_bib23","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1093\/rheumatology\/kex336","article-title":"Interleukin-6 flags infection in tocilizumab-treated giant cell arteritis","volume":"57","author":"Berger","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.heliyon.2023.e16665_bib24","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1007\/s00296-020-04705-2","article-title":"Utility of the neutrophil-to-lymphocyte ratio for predicting bacterial infection in patients with rheumatoid arthritis receiving Tocilizumab","volume":"40","author":"Nagai","year":"2020","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.heliyon.2023.e16665_bib25","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1097\/INF.0b013e318295a3d0","volume":"32","author":"Gaensbauer","year":"2013","journal-title":"Astur. E.J. Procalcitonin. Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.heliyon.2023.e16665_bib26","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3109\/s10165-009-0223-8","article-title":"Neutrophil CD64 as a marker of infection in patients treated with tocilizumab","volume":"19","author":"Matsui","year":"2009","journal-title":"Mod. Rheumatol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023038720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023038720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:37:34Z","timestamp":1790469454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023038720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S2405844023038720"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e16665","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced C-reactive protein level at hospital admission in patients treated with Tocilizumab \u2013 An attention may be required","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e16665","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e16665"}}